45th Annual Meeting of the European Association for the Study of Diabetes
Vienna, Austria, 29 September - 2 October, 2009
WORCESTER, Mass., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it is presenting study results at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD, www.easd.org) being held in Vienna, Austria, 29 September - 2 October, 2009 (www.easd2009.com).
An abstract entitled Management of Impaired Glucose Tolerance using Buccal Spray Insulin is a poster presentation at the symposium. The abstract presents data supporting the conclusion that Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, is a simple and valuable therapy for reducing postprandial hyperglycaemia in obese subjects with Impaired Glucose Tolerance. The results indicate that the treatment is safe and none of the study subjects experienced hypoglycaemia. The abstract's authors concluded that the use of insulin through an alternative route such as the buccal mucosa can represent a novel approach for treatment of postprandial hyperglycaemia.
An abstract entitled Glucose RapidSpray(TM): An Innovative Tool to Control Hypoglycaemia and Improve HbA1c in Children with Type 1 Diabetes is a poster presentation at the symposium. The authors of the abstract note that a more acceptable and practical tool to control and manage hypoglycaemia, especially in toddlers and young children, represents a very relevant therapeutic issue. The abstract presents data supporting the conclusion the Glucose RapidSpray(TM), the Company's proprietary oral glucose spray product, is able not only to reduce the risk of hypoglycaemia but to improve overall metabolic control, as shown by a reduction of HbA1c.
The EASD Annual Meeting, which brings together more than 14,000 delegates in the healthcare industry, is a premier platform for professional exchange in the field of diabetes. The EASD brings together scientists, physicians, laboratory workers, nurses, and students from all over the world who are interested in diabetes and related subjects.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.